Literature DB >> 3494371

A radioimmunoassay for bone Gla protein (BGP) in human plasma.

J S Johansen, J E Mølholm Hansen, C Christiansen.   

Abstract

To study the value of bone Gla protein (BGP) as a biochemical marker of normal bone physiology and metabolic bone disorders, we have developed a radioimmunoassay (RIA) for the detection of BGP in human plasma. Antibodies were generated in rabbits immunized with purified calf BGP conjugated to thyroglobulin. Human plasma BGP reacted identically with the calf BGP standard, thus demonstrating the suitability of the assay to measure plasma BGP levels in man. The RIA is sensitive, accurate, and technically simple. Plasma BGP levels were determined in normal subjects (N = 35) and in patients with hypothyroidism (N = 10), hyperthyroidism (N = 22) and chronic renal failure (N = 35). The mean (+/- 1 SEM) concentration of plasma BGP in normal subjects was 1.27 +/- 0.07 nmol/l. Plasma BGP was significantly increased in patients with hyperthyroidism, 4.04 +/- 0.78 nmol/l (P less than 0.001) and chronic renal failure, 10.17 +/- 2.47 nmol/l (P less than 0.001). Low concentrations were found in patients with hypothyroidism, 0.74 +/- 0.11 nmol/l (P less than 0.01). Our studies indicate that plasma BGP provides a useful technique in the diagnosis of patients with bone disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494371     DOI: 10.1530/acta.0.1140410

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  18 in total

1.  Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen.

Authors:  C Hassager; J Risteli; L Risteli; C Christiansen
Journal:  Osteoporos Int       Date:  1994-11       Impact factor: 4.507

2.  New methods for identifying "at risk" patients for osteoporosis.

Authors:  C Christiansen; B J Riis
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

3.  Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy.

Authors:  B J Riis; K Overgaard; C Christiansen
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

4.  Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.

Authors:  N M Nielsen; P von der Recke; M A Hansen; K Overgaard; C Christiansen
Journal:  Calcif Tissue Int       Date:  1994-07       Impact factor: 4.333

5.  Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.

Authors:  K Overgaard
Journal:  Calcif Tissue Int       Date:  1994-08       Impact factor: 4.333

6.  Human growth hormone and growth hormone releasing hormone: a double-masked, placebo-controlled study of their effects on bone metabolism in elderly women.

Authors:  B Clemmesen; K Overgaard; B Riis; C Christiansen
Journal:  Osteoporos Int       Date:  1993-12       Impact factor: 4.507

7.  Long-term treatment of established osteoporosis with intranasal calcitonin.

Authors:  K Overgaard; C Christiansen
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

8.  Types I and III procollagen extension peptides in serum respond to fracture in humans.

Authors:  S Joerring; L T Jensen; G R Andersen; J S Johansen
Journal:  Arch Orthop Trauma Surg       Date:  1992       Impact factor: 3.067

9.  Increased rat femur osteocalcin mRNA concentrations following in vivo administration of thyroid hormone.

Authors:  D S Ross; R Graichen
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

10.  Comparison of vitamin D metabolism in early healthy and late osteoporotic postmenopausal women.

Authors:  D Hartwell; B J Riis; C Christiansen
Journal:  Calcif Tissue Int       Date:  1990-12       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.